

Postprandial glycaemic excursions and cardiovascular risk

Rajendra Pradeepa¹, Viswanathan Mohan²

During the last few years there is increasing recognition regarding the role of postprandial hyperglycaemia (PPHG) in contributing to the development of micro- and macrovascular complications of diabetes. PPHG has a harmful effect on the vascular endothelium, which is mainly mediated by oxidative stress. Numerous epidemiological and longitudinal studies have shown elevated PPHG to be an independent risk factor for cardiovascular disease and increased mortality risk. In addition, PPHG contributes significantly to glycosylated haemoglobin levels particularly in relatively well controlled type 2 diabetic subjects. PPHG is thus emerging as a valid therapeutic target to minimise cardiovascular disease risk. This review looks at the association of postprandial excursions and the risk for cardiovascular disease.

[*J Indian Med Assoc* 2011; 109: 912-20]

Key words : Postprandial hyperglycaemia, cardiovascular risk, diabetes, postprandial excursions.

Type 2 diabetes mellitus is one of the most common metabolic disorders, characterised by abnormalities in insulin action (insulin resistance) and insulin secretion (pancreatic beta-cell dysfunction)^{1,2}. In the natural history of type 2 diabetes mellitus, it is the postprandial plasma glucose level that rises initially (stage of impaired glucose tolerance) even before the fasting plasma glucose levels begin to increase. The pancreas responds by secreting much higher insulin levels in an effort to keep the postprandial glucose values under check. With time, the ability of the pancreas to secrete such supraphysiological doses of insulin diminishes (Starling's law of the pancreas) and overt diabetes results with an increase in fasting plasma glucose (FPG) as well³. The Diabetes Control and Complications Trial (DCCT)⁴, the United Kingdom Prospective Diabetes Study (UKPDS)⁵ and the Kumamoto study⁶ have all demonstrated that maintaining glycaemic control to levels as close to physiological levels, prevents the development and progression of microvascular disease and to some extent macrovascular complications as well.

Traditionally the fasting plasma glucose has been the standard to assess the control of diabetes and the efforts to control the postprandial plasma glucose were not very aggressive. However, the recent focus on the contribution of the postchallenge or postprandial hyperglycaemia (PPHG) to the development of complications has changed the attitude of physicians as now the postprandial plasma glucose receive similar attention as the fasting plasma glucose. Indeed, postprandial glycaemic excursions do contribute to the sustained hyperglycaemia of diabetes⁷. Ac-

cording to Monnier^{8,9}, the postprandial period lasts at least for four to six hours after a meal, followed by a postabsorptive period. Using 24-hour continuous glucose monitoring system it has been shown that deterioration of glucose homeostasis in individuals with type 2 diabetes occurs in stages with an initial loss of postprandial glycaemic control, which progresses later to fasting hyperglycaemia.

There is continuing debate as to what degree of postprandial glucose contributes to the development of microvascular and macrovascular complications. Recent studies^{10,11} have found PPHG to be an independent risk factor for cardiovascular comorbidities and all-cause mortality in diabetes. In this article we will discuss about postprandial excursions and the risk for cardiovascular disease.

Definition of Postprandial Hyperglycaemia (PPHG) :

The term 'postprandial' is broadly defined as the period following meal, therefore, postprandial hyperglycaemia refers to plasma glucose concentrations after eating¹². Generally in diabetic individuals the plasma glucose levels start to increase 10 minutes after the start of a meal and in non-diabetic individuals peak around 1 hour later, rarely crossing 140mg/dl. It returns to preprandial levels by 2 to 3 hours. The profile of postprandial hyperglycaemia is determined by multiple factors including the timing, quantity and composition of the meal, carbohydrate content (both quantity and quality), insulin and glucagon secretion, etc. Because the absorption of food persists for 5 to 6 hours, this makes it difficult to define the time at which the postprandial value has to be measured. It is generally the 2-hour postplasma glucose that is used but some centres use the 1.5 hours value. Since differences in diet habits

Madras Diabetes Research Foundation and Dr Mohan's Diabetes Specialities Centre, Chennai 600086

¹PhD, Senior Scientist and Head of Research Operation

²MD, FRCP (Lond, Edin, Glasg & Ireland), PhD, DSc, Director and Chief of Diabetes Research

and preferences between various cultures, and even within the same day (eg, breakfast, lunch and dinner) can markedly reflect the glycaemic excursions, it is difficult to fix a standard time for taking the postprandial sample and it largely depends on local customs and habits¹³.

However, the American Diabetes Association has suggested that in general, a measurement of plasma glucose 2 hours after the start of a meal is practical, generally approximates the peak value in patients with diabetes, and provides a reasonable assessment of PPHG¹⁴.

Relationship between Postprandial Hyperglycaemia and Cardiovascular Risk:

Cardiovascular disease accounts for most of the increased morbidity and mortality associated with type 2 diabetes¹⁵. An acute elevation of the plasma glucose level triggers a series of tissue responses that may contribute to the development of macrovascular complications of diabetes. Concomitant increase of glycaemia in the postprandial phase can amplify an increase in cardiovascular risk factors while producing by itself several functional alterations favouring cardiovascular disease¹⁶. According to Haller¹⁷ the development of atherosclerosis often predates a diagnosis of type 2 diabetes and it is possible that postprandial changes contribute to atherosclerosis before fasting plasma glucose concentrations are elevated. Indeed there is increasing evidence that PPHG is an important contributing factor for the development of atherosclerosis in non-diabetic individuals. There are also several experimental studies that have demonstrated the potential proatherogenic role of PPG peaks¹⁸.

Numerous cross-sectional and prospective epidemiological studies, mostly using the oral glucose tolerance test, have shown elevated postprandial/postglucose challenge values to be independent risk factors for macrovascular complications and increased mortality risk. Table 1 provides various studies¹⁹⁻³⁸ reporting on association of postprandial hyperglycaemia with risk of cardiovascular disease since 1979. The Honolulu Heart Study²³ found a strong correlation between postchallenge glucose levels and the incidence of cardiovascular mortality. The German Diabetes Intervention Study²⁴, which followed newly diagnosed patients with type 2 diabetes, found moderate postprandial hyperglycaemia to be more indicative of atherosclerosis than was fasting glucose, and found postprandial, but not fasting glucose to be an independent risk factor for cardiovascular mortality. A meta-analysis which included 95,783 subjects followed on average for 12.4 years, demonstrated an exponential relationship between the incidence of cardiovascular events and the 2-hours PPG²⁸. Similar to these findings, de Vegt *et al*³⁰ found that the degree of risk conferred by the 2-hour postpran-

dial glucose concentration was nearly twice that conferred by glycated haemoglobin level. The DECODE Study³⁵, which followed more than 25,000 subjects for a mean period of 7.3 years, confirmed that, the 2-hour postchallenge hyperglycaemia after an OGTT is associated with increased mortality, and also that, the postchallenge glucose level is a better predictor of mortality than the fasting plasma glucose level.

Cavalot *et al*³⁸ in the San Luigi Gonzaga Diabetes Study in a 5-year follow-up type 2 diabetic subjects have concluded that postprandial, but not fasting, blood glucose is an independent risk factor for cardiovascular events, with a stronger predictive power in women than in men. The same group after a 14-year follow-up recently have again demonstrated that both postprandial blood glucose and HbA1c predicts CVD events and all-cause mortality in diabetic subjects.

Additionally, the Helsinki Policemen study conducted in early 1980s²² and the Paris Prospective Study done in early 1990s³⁹ have also demonstrated that postprandial hyperinsulinaemia is an independent risk factor for macrovascular complications. Longitudinal studies conducted in Mauritius, Fiji and Nauru have shown that isolated postchallenge hyperglycaemia (≥ 11.1 mmol/l) with normal fasting plasma glucose (<7.0 mmol/l) doubles the risk of mortality³⁰. Similarly, in the Rancho Bernardo Study, isolated postchallenge hyperglycaemia was a predictor of fatal cardiovascular disease (CVD) in older women and men.

Some, studies^{23,25,40} have demonstrated that even moderate postprandial hyperglycaemia (148-199 mg/dl) is not only more indicative of atherosclerosis than is fasting glucose, but also may have direct adverse effects on the endothelium. A recent study by Mah *et al*⁴¹ hypothesise that postprandial hyperglycaemia would decrease vascular function in healthy men by inducing oxidative stress and proinflammatory responses and increasing asymmetric dimethylarginine:arginine (ADMA:arginine), a biomarker that is predictive of reduced NO biosynthesis. Many alterations found in the postprandial state could initiate a cascade of proatherogenic disturbances, which leads to endothelial dysfunction and plaque instability and furthermore, a rapid decrease in flow mediated vasodilatation has also been demonstrated in the postprandial phase in type 2 diabetic patients which is inversely correlated with the magnitude of PPHG⁴².

Experimental studies have also shown a link between carotid intima media thickness (IMT), a surrogate marker for atherosclerosis and PPHG¹⁸. The RIAD (Risk factors in Impaired glucose tolerance for Atherosclerosis and Diabetes) study¹⁹, conducted in 119 subjects showed that 2-hours PPG correlated better than FPG with carotid IMT. In another study¹⁸ conducted in 582 subjects with varying degrees of glucose intolerance, 2-hours PPG was found to

Table 1 — Studies on Association of Postprandial Hyperglycaemia with Risk of Cardiovascular Disease

Study/year	Study	No of cases	Follow-up in years	Conclusions
Pyorala <i>et al</i> (1979) ²⁰	Social Insurance Institution's (SII) Coronary Heart Disease Study and Helsinki Policemen Study	4326	4 years in SII and 10 years in Helsinki Policemen study	1-hour and 2-hour OGTT glucose predicted incidence CHD risk
Jarrett <i>et al</i> (1982) ²¹	Bedford Study	241	10	Protection was in CAD was lost in patients with increased PPG
Pyorala <i>et al</i> (1985) ²²	Helsinki Policemen Study	982	9.5	2-hour OGTT glucose predicted incidence CAD better than FPG
Donahue <i>et al</i> (1987) ²³	Honolulu Heart Programme	6394	12	Strong correlation between PPG levels and the incidence of cardiovascular mortality
Jackson <i>et al</i> (1992) ²⁴	Islington Diabetes Survey	223	-	2-hour glucose –better predictor of CAD than HbA1c
Vaccaro <i>et al</i> (1992) ²⁵	Chicago Peoples Gas Company Study	873	19	PPG is associated with coronary and cardiovascular mortality independent of other factors
Hanefeld <i>et al</i> (1996) ²⁶	German Diabetes Intervention Study	984	11	2-hour PPG but not fasting glucose is associated with increased all-cause and CVD mortality.
Balkau <i>et al</i> (1998) ²⁷	Whitehall Study, Paris Prospective Study and Helsinki Policeman Study	17,000	20	2-hour PPG associated with increased all-cause and CVD mortality
Barrett-Connor and Ferrare (1998) ²⁸	Rancho Bernardo Study	1,858	7	Isolated PPG doubles the risk-fatal CVD and heart disease in older women and men
Coutinho <i>et al</i> (1999) ²⁹	Meta-analysis of 20 studies	95,783	12	Progressive relationship between FPG and 2-hour glucose and CVD
De Vegt <i>et al</i> (1999) ³⁰	Hoorn Study	2,363	8	2-hour-glucose –better predicts mortality than HbA1c and increases CVD mortality by 62%
Shaw <i>et al</i> (1999) ³¹	-	9,179	5-12	Isolated PPG doubled the mortality risk
Tominaga <i>et al</i> (1999) ³²	Funagata Diabetes Study	2,651	7	IGT – a risk factor for CVD, but not IFG
Barzilay <i>et al</i> (1999) ³³	Cardiovascular Health Study	4,515	8	Subjects with IGT – 22% increased risk of CVD compared with NGT subjects
Saydah <i>et al</i> (2001) ³⁴	National Health and Nutrition Examination Survey (NHANES) Mortality Study	3,174	12-16	Relative risk for death from CVD – 20% more in IGT and 70% in previously undiagnosed type 2 diabetes
DECODE Study Group (2001) ³⁵	Diabetes Epidemiology Collaborative analysis of Diagnostic criteria in Europe (DECODE) Study	25,364	10	2-hour PPG is associated with increased mortality, and a better predictor than FPG level
Meigs <i>et al</i> (2002) ³⁶	Framingham OffSpring Study	3,370	4	2-hour glucose predicts CVD events better than HbA1c
Esposito <i>et al</i> (2004) ³⁷	Campanian Postprandial Hyperglycaemia Study	75	1	Reduction of PPG is associated with carotid intima media thickness
Cavalot <i>et al</i> (2006) ³⁸	San Luigi Gonzaga Diabetes Study	529	5	PPG, but not FPGs an independent risk factor in women than men for cardiovascular events in type 2 diabetes
Cavalot <i>et al</i> (2011) ³⁹	San Luigi Gonzaga Diabetes Study	505	14	Both PPG and HbA1c predict cardiovascular events and all-cause mortality

OGTT: Oral glucose tolerance test; PPG : Postprandial glucose; CAD: Coronary artery disease; CVD: Cardiovascular disease; FPG: Fasting plasma glucose; HbA1c: Glycosylated haemoglobin; IGT: Impaired glucose tolerance; IFG: Impaired fasting glucose; NGT: Normal glucose tolerance

be the most important glycaemic determinant of carotid IMT, compared to HbA1c or FPG.

Evidence also suggests that control of PPHG may reduce the development of CVD. There are few intervention studies which showed that by controlling PPGH there was a reduced risk of the development of cardiovascular events⁴³ and also a significant decrease in the progression of carotid IMT^{36,44}. However the recent multinational, randomised, controlled trial, the Hyperglycaemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D)⁴⁵, which compared the effects of prandial *ver-*

sus fasting glycaemic control on risk for cardiovascular outcomes in patients with type 2 diabetes after acute myocardial infarction (AMI) identified a linear relationship between the risk of CVD death and PPHG¹¹. According to Ceriello⁴⁵, negative result of the HEART2D study is in line with the ACCORD trial⁴⁶, ADVANCE study⁴⁷, longterm follow-up of the UK Prospective Diabetes Study⁴⁸ and STOPNIDDM⁴⁴ studies. It appears that if the control of hyperglycaemia (either fasting [ACCORD and ADVANCE] or postprandial [HEART2D]) is started too late, the possible beneficial effect of treating hyperglycaemia with re-

spect to preventing CVD may be lost.

It has been shown that PPHG leads to postprandial lipaemia (mainly triglyceride rich particles and free fatty acids), a state during which lipoprotein moieties of high atherogenicity circulate in the blood⁴⁸⁻⁵⁰. In a study investigating the effects of postprandial lipaemia on CIMT, postprandial triglycerides had the strongest correlation with CIMT, although PPHG, postprandial triglycerides and fasting LDL-C levels were all independently related⁵⁰. Enhanced lipid peroxidation is also associated with postprandial elevations of blood glucose^{51,52}, leading to oxidative stress which may contribute to the development of micro- and macrovascular complications of diabetes mellitus.

Conclusions :

Nearly 75% of mortality in individuals with type 2 diabetes can be accounted for by CVD. It is now being increasingly realised that PPHG plays an important role in the development of macrovascular and microvascular complications in individuals with diabetes and impaired glucose tolerance. During PPHG, hyperglycaemic spikes cause endothelial dysfunction, inflammatory reactions and oxidative stress, which may lead to progression of atherosclerosis and occurrence of cardiovascular events. There is an alarming body of epidemiological and interventional evidence suggesting that postprandial, but not fasting hyperglycaemia, independently predicts CVD events. Thus attempts should be made to correct PPHG in addition to FPG, to reduce the risk of CVD and the earlier these strategies are initiated the better would be the outcomes.

REFERENCES

- DeFronzo RA — Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. *Diabetes* 1988; **37**: 667-87.
- Bogardus C — Diabetes Mellitus. Philadelphia PA: Lippincott-Raven Publishers, 1996.
- Jones DB, Gill GV — Non insulin dependent diabetes mellitus. In: Pickup J, Williams G, editors. Textbook of Diabetes Mellitus. 2nd ed. New York: John Wiley and Sons, 1997: 17.6-13.
- The Diabetes Control and Complications Trial Research Group — The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. *N Engl J Med* 1993; **329**: 977-86.
- UK Prospective Diabetes Study (UKPDS) Group — Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998; **352**: 837-53.
- Shichiri M, Kishikawa H, Ohkubo Y, Wake N — Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. *Diabetes Care* 2000; **23**: B21-B29.
- Slama G — Clinical significance of post-prandial blood glucose excursions in Type 1 and Type 2 diabetes mellitus. *Int J Clin Pract* 2000; **112**: 9-12.
- Monnier L — Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? *Eur J Clin Invest* 2000; **30**: 3-11.
- Monnier L, Colette C, Dunseath GJ, Owens DR — The loss of postprandial glycaemic control precedes stepwise deterioration of fasting with worsening diabetes. *Diabetes Care* 2007; **30**: 263-9.
- Hanefeld M — Postprandial hyperglycaemia: noxious effects on the vessel wall. *Int J Clin Pract Suppl* 2002; **129**: 45-50.
- Bonora E, Muggeo M — Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. *Diabetologia* 2001; **44**: 2107-14.
- Raz I, Wilson PWF, Strojek K, Kowalska I, Bozikov V, Gitt AK, et al — Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. *Diabetes Care* 2009; **32**: 381-6.
- Ceriello A — The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. *Diabetologia* 2003; **46**: M9-M16.
- Mohan V, Sudhir R, Pradeepa R — Postprandial hyperglycaemia. In: Bhattacharya PK, editor. The Association of Physicians of India, Assam State Chapter. Medicine Update. Guwahati: API, 2003: 546-52.
- American Diabetes Association — Postprandial glucose. *Diabetes Care* 2001; **24**: 775-8.
- Bonora E, Muggeo M — Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. *Diabetologia* 2001; **44**: 2107-14.
- Haller H — Postprandial glucose and vascular disease. *Diabet Med* 1997; **14**: S50-S56.
- Ceriello A — The postprandial state and cardiovascular disease; relevance to diabetes mellitus. *Diabetes Metab Res Rev* 2000; **16**: 125-32.
- Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T — Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: The RIAD Study. Risk factors in impaired glucose tolerance for atherosclerosis and diabetes. *Diabet Med* 2000; **17**: 835-40.
- Pyorala K — Relationship of glucose intolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. *Diabetes Care* 1979; **2**: 131-41.
- Jarrett RJ, McCartney P, Keen H — The Bedford Survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycemic controls and risk indices for coronary heart disease in borderline diabetics. *Diabetologia* 1982; **22**: 79-84.
- Pyorala K, Savolainen E, Kaukola S, Haapakoski J — Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9½ year followup of the Helsinki Policemen Study population. *Acta Med Scand Suppl* 1985; **701**: 38-52.
- Donahue RP, Abbott RD, Reed DM, Yano K — Post challenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. *Diabetes* 1987; **36**: 689-92.
- Jackson CA, Yudkin JS, Forrest RD — A comparison of the relationships of the glucose tolerance test and the glycated hemoglobin assay with diabetic vascular disease in the community. The Islington Diabetes Survey. *Diabetes Res Clin Pract* 1992; **17**: 111-23.
- Vaccaro O, Ruth KJ, Stamler J — Relationship of postload plasma glucose to mortality with 19-year follow-up: comparison of one versus two plasma glucose measurements in the Chicago Peoples Gas Company Study. *Diabetes Care* 1992; **15**: 1328-34.
- Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al — Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. *Diabetologia* 1996; **39**: 1577-83.
- Balkau B, Pyorala M, Shipley M, Pyorala K, Pyorala M, Forhan

- A, *et al* — High blood glucose concentration is a risk factor for mortality in middle aged non-diabetic men: 20-year follow-up to the Whitehall Study, the Paris Prospective Study and the Helsinki Policeman Study. *Diabetes Care* 1998; **21**: 360-7.
- 28 Barrett-Connor E, Ferrara A — Isolated post challenge hyperglycaemia and the risk of fatal cardiovascular disease in older women and men. *Diabetes Care* 1998; **21**: 1236-9.
- 29 Coutinho M, Gerstein HC, Wang Y, Yusuf F — The relationship between glucose and incident cardiovascular events: a meta regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. *Diabetes Care* 1999; **22**: 233-40.
- 30 de Veegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, *et al* — Hyperglycemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. *Diabetologia* 1999; **42**: 926-31.
- 31 Shaw JE, Hodge AM, Courten M de, Chitson P, Zimmet PZ — Isolated post-challenge hyperglycemia confirmed as a risk factor for mortality. *Diabetologia* 1999; **42**: 1050-4.
- 32 Tominaga M, Igarashi K, Eguchi H, Igarashi K, Kato T, Sekikawa A — Impaired glucose tolerance is a risk factor for cardiovascular disease but not impaired fasting glucose. *Diabetes Care* 1999; **22**: 920-4.
- 33 Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD, *et al* — Cardiovascular disease in older adults with glucose disorders: a comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. *Lancet* 1999; **354**: 622-5.
- 34 Saydah SH, Loria CM, Eberhardt MS, Brancati FL — Sub-clinical states of glucose intolerance and risk of death in the US. *Diabetes Care* 2001; **24**: 447-53.
- 35 DECODE study group, on behalf of the European Diabetes Epidemiology Group — Diabetes Epidemiology: collaborative analysis of Diagnostic Criteria in Europe. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association Diagnostic criteria. *Lancet* 1999; **354**: 617-21.
- 36 Meigs JB, Nathan DM, D'Agostino RB, Wison PW — Fasting and post-challenge glycaemia and cardiovascular disease risk: The Framingham Offspring Study. *Diabetes Care* 2002; **25**: 1845-50.
- 37 Esposito K, Giugliano D, Nappo F, Marfella R, for the Campanian Post-prandial Hyperglycemia Study Group — Regression of carotid atherosclerosis by control of post-prandial hyperglycemia in type 2 diabetes mellitus. *Circulation* 2004; **110**: 214-9.
- 38 Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, *et al* — Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. *J Clin Endocrinol Metab* 2006; **91**: 813-9.
- 39 Cavalot F, Pagliarino A, Valle M, Di Martino L, Bonomo K, Massucco P, *et al* — Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the san luigi gonzaga diabetes study. *Diabetes Care* 2011; **34**: 2237-43.
- 40 Fontbonne AM, Eschwege EM — Insulin and cardiovascular disease: Paris Prospective Study. *Diabetes Care* 1991; **14**: 461-9.
- 41 Mah E, Noh SK, Ballard KD, Matos ME, Volek JS, Bruno RS — Postprandial hyperglycemia impairs vascular endothelial function in healthy men by inducing lipid peroxidation and increasing asymmetric dimethylarginine:arginine. *J Nutr* 2011; **141**: 1961-8.
- 42 Hanefeld M, Schaper F — Prandial hyperglycemia: is it important to track and treat? *Curr Diabetes Rep* 2005; **5**: 333-9.
- 43 Shige H, Ishikawa T, Suzukawa M, Ito T, Nakajima K, Higashi K, *et al* — Endothelium dependant flow-mediated vasodilatation in the post prandial state in type 2 diabetes mellitus. *Am J Cardiol* 1999; **64**: 885-8.
- 44 Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M — Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial. *Lancet* 2002; **359**: 2072-7.
- 45 Ceriello A — Postprandial Hyperglycemia and cardiovascular disease: is the HEART2D study the answer? *Diabetes Care* 2009; **32**: 521-2.
- 46 Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, *et al* — Effects of intensive glucose lowering in type 2 diabetes. Action to Control Cardiovascular Risk in Diabetes Study Group. *N Engl J Med* 2008; **358**: 2545-59.
- 47 Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, *et al* — Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ADVANCE Collaborative Group. *N Engl J Med* 2008; **358**: 2560-72.
- 48 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA — 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008; **359**: 1577-89.
- 49 Patsch JR, Miesenbock G, Hopferweiser T, Muhlberger V, Knapp E, Dunn JK, *et al* — Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. *Arterioscler Thromb* 1992; **12**: 1336-45.
- 50 Ginsberg HN, Jones J, Blaner WS, Thomas A, Karmally W, Fields L, *et al* — Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise – induced myocardial ischaemia in middle aged men and women. *Arterioscler Thromb Vasc Biol* 1995; **15**: 1829-38.
- 51 Teno S, Uto Y, Nagashima H, Endoh Y, Iwamoto Y, Omori Y, *et al* — Association of postprandial hypertriglyceridaemia and carotid intima-media thickness in patients with type 2 diabetes. *Diabetes Care* 2000; **23**: 1401-6.
- 52 Wehmeier KR, Mooradian AD — Autooxidative and antioxidative potential of simple carbohydrates. *Free Radic Biol Med* 1994; **17**: 83-6.

The appearance of advertisement in JIMA publication is not a guarantee or endorsement of the product or the claims made for the product by the manufacturer.

— Hony Editor

Attention ! IMA Local Branch Secretaries

As per direction of the Hony Secretary General, you are requested not to send directly the branch news/activities to the JIMA for publication.

You should send the same to Hony Secretary General, IMA (HQ), New Delhi-110002 and they will send to us subsequently.

Please bear with us !

— Hony Secretary, JIMA